Last Updated:
September 6,2014Original Published:
September 6,2014Tofacitinib (Xeljanz®) is the first of a unique class of oral kinase inhibitors to be FDA approved for the treatment of rheumatoid arthritis (RA). Tofacitinib is a selective inhibitor of Janus kinase (JAK) enzymes. these enzymes mediate signaling for several important cytokines that cause the inflammation in Rheumatoid Arthritic patients.